quinagolide

Known as: N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propyl-3-benzo(g)quinolinyl)sulfamide, (3alpha,4aalpha,10abeta)-(+-)-isomer, quinagolide, (3alpha,4aalpha,10abeta)-(+-)-isomer 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
In most mammals, prolactin (PRL) is essential for maintaining lactation, and yet the short-term suppression of PRL during… (More)
Is this relevant?
2007
2007
The relationship between endocrine regulation and immune system has recently become the subject of intense investigations. The… (More)
Is this relevant?
2001
2001
The objective of this study was to determine the effect of quinagolide (Norprolac) on serum level of cytokines in systemic lupus… (More)
Is this relevant?
2000
2000
OBJECTIVE To compare effectiveness and tolerability of quinagolide (CV 205-502) and cabergoline (CAB) treatments in 39 patients… (More)
Is this relevant?
2000
2000
Quinagolide (QUI) and cabergoline (CAB) are dopamine agonists recently introduced for the treatment of hyperprolactinemia. In the… (More)
Is this relevant?
Highly Cited
2000
Highly Cited
2000
To investigate whether previous treatment with bromocriptine (BRC) or quinagolide (CV) impairs a subsequent response to long-term… (More)
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia… (More)
Is this relevant?
1996
1996
Resistance to bromocriptine, defined as the absence of normalization of prolactin (PRL) levels despite a 15-30 mg daily dose of… (More)
  • table I
  • table 2
  • figure 1
  • figure 2
  • figure 4
Is this relevant?
1994
1994
Cabergoline and quinagolide, two new dopamine agonist drugs with long-lasting activity, are currently under investigation for the… (More)
Is this relevant?
1994
1994
OBJECTIVE To audit the efficacy of quinagolide (CV205-502, Norprolac, Sandoz) in lowering prolactin, and its tolerability, in… (More)
Is this relevant?